CA3212339A1 - Method of treating a condition using a therapeutically effective dose of the malt1 inhibitor jnj -67856633 (1 -(1 -oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifl uoromethyl)pyridin-4-yl)-1 h-py razole-4-carboxamide) - Google Patents

Method of treating a condition using a therapeutically effective dose of the malt1 inhibitor jnj -67856633 (1 -(1 -oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifl uoromethyl)pyridin-4-yl)-1 h-py razole-4-carboxamide) Download PDF

Info

Publication number
CA3212339A1
CA3212339A1 CA3212339A CA3212339A CA3212339A1 CA 3212339 A1 CA3212339 A1 CA 3212339A1 CA 3212339 A CA3212339 A CA 3212339A CA 3212339 A CA3212339 A CA 3212339A CA 3212339 A1 CA3212339 A1 CA 3212339A1
Authority
CA
Canada
Prior art keywords
compound
cancer
therapeutically effective
effective dose
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3212339A
Other languages
English (en)
French (fr)
Inventor
Anthony T. GREWAY
Ulrike Philippar
Thomas C. WILDE
Marie E. WILLEMIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA3212339A1 publication Critical patent/CA3212339A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3212339A 2021-03-03 2021-03-03 Method of treating a condition using a therapeutically effective dose of the malt1 inhibitor jnj -67856633 (1 -(1 -oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifl uoromethyl)pyridin-4-yl)-1 h-py razole-4-carboxamide) Pending CA3212339A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2021/051776 WO2022185097A1 (en) 2021-03-03 2021-03-03 Method of treating a condition using a therapeutically effective dose of the malt1 inhibitor jnj -67856633 (1 -(1 -oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1 h-py razole-4-carboxamide)

Publications (1)

Publication Number Publication Date
CA3212339A1 true CA3212339A1 (en) 2022-09-09

Family

ID=74860360

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3212339A Pending CA3212339A1 (en) 2021-03-03 2021-03-03 Method of treating a condition using a therapeutically effective dose of the malt1 inhibitor jnj -67856633 (1 -(1 -oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifl uoromethyl)pyridin-4-yl)-1 h-py razole-4-carboxamide)

Country Status (10)

Country Link
US (1) US20240299376A1 (https=)
EP (1) EP4301364A1 (https=)
JP (1) JP2024508890A (https=)
KR (1) KR20230154227A (https=)
CN (1) CN117279639A (https=)
AU (1) AU2021431485A1 (https=)
BR (1) BR112023017689A2 (https=)
CA (1) CA3212339A1 (https=)
MX (1) MX2023010322A (https=)
WO (1) WO2022185097A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
EP3953345B1 (en) 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Pyridine rings containing derivatives as malt1 inhibitors
CN118451068A (zh) * 2021-12-30 2024-08-06 上海翰森生物医药科技有限公司 三并环类衍生物抑制剂、其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
US12269813B2 (en) 2019-02-22 2025-04-08 Janssen Pharmaceutica Nv Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide monohydrate
US20220175760A1 (en) * 2019-02-22 2022-06-09 Janssen Pharmaceutica Nv Pharmaceutical formulations

Also Published As

Publication number Publication date
EP4301364A1 (en) 2024-01-10
WO2022185097A1 (en) 2022-09-09
CN117279639A (zh) 2023-12-22
JP2024508890A (ja) 2024-02-28
AU2021431485A1 (en) 2023-10-19
MX2023010322A (es) 2023-11-24
BR112023017689A2 (pt) 2023-11-14
US20240299376A1 (en) 2024-09-12
KR20230154227A (ko) 2023-11-07

Similar Documents

Publication Publication Date Title
US20230121530A1 (en) Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
CN105873440B (zh) 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
JP7667568B2 (ja) 複素環キナーゼ阻害剤及びその使用
JP6382949B2 (ja) 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
US20170143726A1 (en) Adenosine receptor agonists and antagonists to modulate t cell responses
CA3212339A1 (en) Method of treating a condition using a therapeutically effective dose of the malt1 inhibitor jnj -67856633 (1 -(1 -oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifl uoromethyl)pyridin-4-yl)-1 h-py razole-4-carboxamide)
CN113164500A (zh) 治疗去势抵抗性和去势敏感性前列腺癌的方法
TW201526897A (zh) 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
JP2019525948A (ja) 薬学的組み合わせ
US20250041277A1 (en) Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
JP2020063269A (ja) 多発性硬化症を治療するための小児科の組成物
WO2014081712A2 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
JP2018504446A (ja) がんを処置するためのｈｓｐ９０阻害剤およびｐｄ−１阻害剤の組み合わせ治療
EP2922546A2 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
US20230130403A1 (en) Methods of treatment with s1p receptor modulators
EP2922826A2 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
US20230165863A1 (en) Methods and formulations for administration of thiocarbamate deriviatives a2a inhibitors
US11376255B2 (en) Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
TW201625253A (zh) 包含ｐｇｄ２拮抗劑之伴隨過敏性疾病之症狀之治療用醫藥
US20210382037A1 (en) Identification and use of cytotoxic t lymphocyte (ctl) antigen-specific target cell killing enhancer agents
WO2020243712A1 (en) Procaspase-3 activation and immunotherapy for treatment of cancer
WO2019164788A1 (en) Methods of treating cancer using aryl dihydro-2h-benzo[b] [1,4]oxazine sulfonamide compounds
HK40116611A (zh) 用於治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案
EA052496B1 (ru) Фармацевтическая композиция, содержащая модулятор рецептора s1p, и способ ее получения

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250826

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251027

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260414